Post di Raffaele Giusti

📣 New offering alert! We're thrilled to announce OncoPortal™ Mutation Tracker— a longitudinal #MRD tracking tool designed for disease monitoring in the context of oncology. This innovation underscores our commitment to advancing data-driven approaches for improved oncology insights. The OncoPortal™ Mutation Tracker augments the SOPHiA DDM™ Platform’s core analytical capabilities to allow clinical researchers to longitudinally monitor evolving genomic variants across multiple time points, providing a comprehensive view of disease evolution. “The ability to reliably track low frequency variants longitudinally is a game-changer because it allows the detection of even the smallest traces of cancer that can evade traditional methods of testing and ultimately drive relapse. With this new longitudinal tracking capability, we offer a highly customizable, user-friendly solution to enable the generation of novel insights for clinical research. Precise tracking of key genomic variants over time has the potential to eventually enable earlier intervention and more tailored disease management, which may lead to better long-term outcomes for patients.” said Philippe Menu, M.D., Ph.D., Chief Medical Officer and Chief Product Officer. Learn more about our offering here: https://lnkd.in/evnuPsyh #DataDrivenMedicine #OncoPortal #Oncology #Cancer

𝗡𝗘𝗪𝗦 𝗙𝗥𝗢𝗠 #𝗔𝗦𝗧𝗥𝗢 𝟮𝟬𝟮𝟰: Linearbeam - Protons for Life 𝗮𝗻𝗱 Leo Cancer Care 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲 𝗮 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝗳𝗼𝗿 #𝗘𝗥𝗛𝗔 𝗣𝗿𝗼𝘁𝗼𝗻 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 We are excited to share, live from #ASTRO2024 in Washington DC, that our company, #LINEARBEAM, dedicated to the commercialization of the next-generation ERHA #protontherapy system, has entered into a commercial partnership with #LeoCancerCare, an international company with extensive experience in upright #radiationtherapy. This strategic alliance will aim to advance ERHA— Enhanced Radiotherapy with HAdrons — by integrating a patient-friendly upright positioning system and CT scanner that seamlessly complements ERHA's advanced #proton therapy #technology, bringing it to the forefront of global cancer treatment #innovation. LINEARBEAM is poised to revolutionize #cancer therapy with its groundbreaking linear #protonaccelerator, the first of its kind. Designed and developed in #Italy, ERHA represents a monumental leap forward in #oncological care. The newly established partnership with Leo Cancer Care aims to innovate together and make an impact on the accessibility of proton therapy treatments worldwide. Together, we are one step closer to a new era in proton therapy, our joint goal is to make #cancertreatment safer, more efficient, and accessible to all. #protons #medicalinnovation #oncology #medtech #businesspartnership #science

November is Lung Cancer Awareness Month. 🎗️ We at SOPHiA GENETICS reaffirm our commitment to excellence and innovation in the fight against this global health challenge.  Our focus on multimodality is evidenced by our DEEP-Lung-IV study, which endeavors to uncover new predictive insights to understand #NSCLC and analyze treatment responses.    🔬 https://lnkd.in/dtt52pfp    Join us in this important conversation and learn how we are working together with hospitals and top cancer centers around the world to advance #DataDrivenMedicine.     #LungCancerAwareness #LungCancer #CancerResearch

🥗 Ketogenic Diet Enhances CAR-T Cell Therapy 🧪 A ketogenic diet might hold the key to enhancing CAR T cell therapy for lymphoma. Researchers from the University of Pennsylvania found that beta-hydroxybutyrate (BHB), a metabolite produced during ketosis, powers CAR T cells more effectively than glucose. In mice, BHB supplementation led to improved tumor control, higher CAR T cell expansion, and, in most cases, complete cancer remission. Translational studies also showed that higher BHB levels correlated with better CAR T cell performance in human samples. A Phase I clinical trial is now underway to test this cost-effective, low-toxicity approach in lymphoma patients. Key Points: 🧬 Ketogenic Boost: Mice on a ketogenic diet exhibited enhanced CAR T cell efficacy, leading to better tumor control and survival. ⚡BHB Preference: CAR T cells use BHB, a metabolite of ketosis, as a preferred energy source over glucose, amplifying their cancer-fighting capabilities. 💉Clinical Trials: A Phase I trial is testing BHB supplementation in lymphoma patients receiving CAR T therapy, with the potential to improve cancer immunotherapy outcomes. #CellTherapy #CART #Lymphoma

Finding the right words can make all the difference, especially when navigating the complexities of living with Diffuse Large B-cell Lymphoma (DLBCL). That is why we are proud to announce a collaborative effort between Sobi and the DLBCL community aimed at providing resources and support for individuals with this debilitating disease.   At the heart of this collaboration lies “The Right Words” discussion guide – a result of close collaboration with DLBCL patients. This guide serves as a roadmap for navigating conversations, offering practical strategies and language tailored to the challenges of living with DLBCL.   We are grateful to the DLBCL community for inspiring this initiative. Together, we can make a meaningful difference—one word at a time. Access the guide https://lnkd.in/dMTyXPET DLBCL, a form of cancer affecting specific white blood cells (B-lymphocytes or B-cells), disrupts the normal signals controlling cell growth and reproduction. Instead, these cells proliferate uncontrollably, leading to significant health challenges.   #Sobi #DLBCL #RightWordsDLBCL

💡 Read our latest Guidelines Spotlight! This year the ESMO Precision Medicine Working Group updated their recommendations for the use of next-generation sequencing (NGS) in advanced cancer. Reflecting advances in the field of precision oncology, the recommendations were expanded to include advanced #BreastCancer and additional rare tumor types. They also encompass the detection of tumor-agnostic alterations in metastatic cancers where access to matched therapies is available. We offer NGS applications that cover key biomarkers highlighted in the recommendations, including SOPHiA DDM™ Dx Homologous Recombination Deficiency (HRD) Solution, which has been recognized by ESMO as a validated method for HRD detection in advanced ovarian cancer. Read our blog to learn more: https://loom.ly/OPxrPKY #NGS #Oncology #ESMO

In recognition of Breast Cancer Awareness Month, we are highlighting our Doxorubicin Hydrochloride reference standard: https://okt.to/h9J87k. This crucial chemotherapy drug plays a significant role in treating not only breast cancer but many other types of cancer. Doxorubicin Hydrochloride works by inhibiting topoisomerase II, which helps slow the growth of cancer cells. Ensure the highest standards in your testing with Mikromol reference standards. #BreastCancerAwareness #Mikromol #CancerResearch #Chemotherapy #PharmaQuality

💡 Revolutionary Mitochondrial Transfer Boosts T Cell Fitness and Antitumor Efficacy💡 👏 Congratulations to Jeremy Baldwin from the group of Luca Gattinoni and Shiladitya Sengupta for their groundbreaking work on intercellular mitochondrial transfer, enhancing T cell metabolic fitness and antitumor efficacy. 🔍 This study introduces a novel platform that leverages bone marrow stromal cells to transfer healthy #mitochondria to CD8+ T cells, overcoming T cell exhaustion—one of the biggest barriers in #immunotherapy for #cancer. By enhancing mitochondrial respiration and resistance to exhaustion, the team showed that mitochondria-boosted T cells could expand more robustly, infiltrate tumors more efficiently, and deliver superior antitumor responses, ultimately prolonging survival in preclinical models. 💊 The findings are highly relevant to the unmet medical need in cancer immunotherapy, particularly for solid tumors. Current therapies often face challenges with T cell #exhaustion due to a hostile tumor #microenvironment. The introduction of this mitochondrial transfer technology represents a significant advancement in organelle medicine, opening new pathways for more effective cell therapies. 🥼 Luca Gattinoni, with his extensive background in immunotherapy and cellular engineering, has been instrumental in pushing the boundaries of adoptive T cell therapies. 🏛️ This work highlights the importance of multidisciplinary and multinational collaborations, demonstrating how joint efforts across institutions like the The National Institutes of Health, LIT - Leibniz Institute for Immunotherapy, Harvard-MIT Health Sciences and Technology (HST) and institutions like the IRCCS Ospedale San Raffaele, showcasing the critical role of global partnerships in pushing the limits of innovation in cancer treatment. 👏 Kudos to the entire research team: Jeremy G. Baldwin, Christoph Heuser-Loy, Tanmoy Saha, Roland C. Schelker, Dragana Slavkovic Lukic, Nicholas Strieder, Inmaculada Hernandez-Lopez, Nisha Rana , Markus Barden, Fabio Mastrogiovanni, Azucena Martín-Santos, Andrea Raimondi, Philip "Zach" Brohawn, Brandon W. Higgs, Claudia G., Veena Kapoor, William G. Telford, Sanjivan G., Maria Xydia, Philipp Beckhove, Sina Frischholz, Kilian Schober, Zacharias Kontarakis, Jacob E. Corn, Matteo Iannacone, Donato Inverso, Michael Rehli, Jessica Fioravanti, Shiladitya Sengupta, and Luca Gattinoni. Read below the full paper ⤵

🌍 We are very proud to have recently joined the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of care! The ELBS pursues a holistic approach to tackling the challenges of clinical implementation in the liquid biopsy field. The network incorporates key players from academia, clinics, industry, and national government agencies to move this promising field forward collectively. 🧬 SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that have helped progress oncology research and tumor mutation profiling. Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). This non-invasive testing allows for cancer genomic profiling and disease monitoring. It reveals critical insights in many cases where genomic testing of tumor tissue may not be feasible due to insufficient tissue material, low quality of the obtained tissue, or the invasiveness of the procedure. 🔗 Learn more about the ELBS: https://loom.ly/3KD9Mic 🔗 Explore our liquid biopsy applications: https://loom.ly/DKKbXGQ #ELBS #LiquidBiopsy #Oncology Klaus Pantel

Age is among the most important cancer risk factors, and the world population is aging, reaching cancer-prone ages. Moreover, treatment improvement increased cancer patients’ lifespan, but survivors’ cancer risk is higher. This increasing cancer burden can only be tempered by an approach in which efforts in disease treatment are paralleled by an increase in its interception. Cancer Driver Interception: here is where real prevention starts. Once intercepted, actionable cancer drivers can be monitored, giving people feedback not only on the progression of the cancer prodromal phase, but also on the effectiveness of the strategies put in place to counteract their presence. Learn more: https://lnkd.in/dKDcMer6 #Oncology #ActivePrevention #Innovation #Helixafe #cancer #cancerdrivers #CancerDriverInterception